Phase 2Status unknown
Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years(COVID-19)
A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years
- Sponsor
- Shenzhen Kangtai Biological Products Co., LTD (Industry)
- Enrollment
- 480 planned
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 Vaccine (Vero Cells), Inactivated; Placebo
- Ages
- children
- Registry
- NCT05003466
Full record on ClinicalTrials.gov
From the registry
This study is a randomized, double-blinded, and placebo controlled phase Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy population aged 3 to 17 years.
Primary outcomes
- Seroconversion rate of SARS-CoV-2 neutralizing antibody
- Geometric mean titer of SARS-CoV-2 neutralizing antibody
History
Study completion
Primary completion
Started
Last registry update
Registered